Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | POLB | P06746 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754291 | 0.91 | KDM4E (0.39) | KDM4EPOLBTDP1THRBSMN1; SMN2 | |
| SCHEMBL25754292 | 0.86 | TSHR (0.33) | ALDH1A1TSHR | |
| SCHEMBL5932801 | 0.82 | KDM4E (0.48) | KDM4EPOLBTDP1THRBSMN1; SMN2 | |
| SCHEMBL25754297 | 0.82 | TSHR (0.33) | TSHR | |
| SCHEMBL25754286 | 0.81 | CA12 (0.32) | TSHRMEN1KMT2A | |
| SCHEMBL25754303 | 0.80 | CYP2C19 (0.38) | TSHRMEN1KMT2A | |
| SCHEMBL5933553 | 0.78 | KDM4E (0.48) | KDM4EPOLBTDP1THRBSMN1; SMN2 | |
| SCHEMBL5932186 | 0.78 | KDM4E (0.48) | KDM4EPOLBTDP1THRBSMN1; SMN2 | |
| SCHEMBL1252986 | 0.78 | KDM4E (0.52) | KDM4EPOLBTDP1THRBSMN1; SMN2 | |
| SCHEMBL24379941 | 0.78 | CYP2C19 (0.39) | KDM4EPOLBTDP1THRBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | KDM4E 2658/4885POLB 4028/4885TDP1 1380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.